<h4>Background</h4>Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in children aged 6-11 years with cystic fibrosis (CF) heterozygous for <i>F508del</i> and a minimal function CF transmembrane conductance regulator (<i>CFTR</i>) variant (<i>F</i>/MF genotypes) in a 24-week, placebo-controlled trial. The gene discussed is CFTR; the disease is cystic fibrosis.